Zydus Lifesciences has reported that its formulations manufacturing facility in Ahmedabad has successfully cleared a pre-approval inspection by the US Food and Drug Administration (USFDA) without any observations.
According to The Economic Times, the inspection was conducted between August 11 and 13, 2025, at the company’s SEZ–II formulations plant. The audit covered three products and reviewed compliance with current Good Manufacturing Practices (cGMP). A pre-approval inspection (PAI) is carried out by the US regulator to confirm that a site mentioned in a new drug application is capable of manufacturing the product as per required standards and that the data submitted for approval is reliable.
The outcome holds strategic significance for Zydus, given that a clear inspection enables smoother progression for product approvals and ensures uninterrupted access to the US market, one of the most competitive and tightly regulated pharmaceutical markets globally. For industry observers, the development underscores the growing importance of Indian facilities in global supply chains, particularly as multinational regulators place increasing scrutiny on manufacturing quality and compliance.
The successful completion of this inspection reflects continuing alignment of Indian drugmakers with evolving USFDA requirements, a trend critical for sustaining export-led growth in the sector.
